-The Hindu The policy fails to acknowledge that IP is a market-driven model’ India’s National Intellectual Property Rights (IPR) policy, unveiled on Friday, could pose a “serious” hurdle to allowing access to affordable drugs and the South Asian nation missed a chance to put in place a progressive policy, according to experts. The policy left the country’s patent laws intact and specifically did not open up Section 3(d) of the Patents Act, which...

-The Hindu In the area of intellectual property, public health and access to medicines, the Narendra Modi government should consider its independence to be of the utmost importance. Strong government leadership as well as flexible intellectual property systems are needed in order to effectively combat drug-resistant tuberculosis (DR-TB) and HIV and also antimicrobial resistance and non-communicable diseases. This is true not only for India but also countries which rely on affordable generic...

-Frontline The government’s passage of the Aadhaar Bill in complete disregard of even basic parliamentary procedures and in subversion of an ongoing judicial process puts at risk a number of constitutional rights and liberties of citizens. The benefits cited are just ploys to realise a neoliberal dream. “Congressmen are dancing as if [Aadhaar] was a herb for all cures. With the Supreme Court pulling up the Centre, people are now seeking...

-The Indian Express Government privileges the private over the public, preferring trade to health In a dramatic development, US industry groups recently claimed the Indian government offered them a “private” assurance that Compulsory licences will not be issued, save in emergencies and for non-commercial purposes. Needless to state, such an assurance flies in the face of the Patents Act and the public health safeguards enshrined in it. Illustratively, Section 84 mandates that...

-TheWire.in The government appears bent on decisively abandoning the earlier consensus of adherence to public health goals. In what is widely being hailed as an extraordinary victory for the multinational pharmaceutical industry over the Indian government, the US-India Business Council (USIBC), in its submission to the United States Trade Representative (USTR), reports that the Indian government has “privately assured” the industry that it would not use Compulsory licences (CLs) for commercial purposes....